HIPPOCOR® Omega–3,6,9 (60 soft gelatine capsules)

HIPPOCOR® Omega–3,6,9 fatty acids from sea buckthorn seeds

FOOD SUPPLEMENT
Registration number within the Food Supplements Register of Latvia: 13869

Sea buckthorn promotes the health of the cardiovascular system and the functioning of the body’s immune system.

One capsule of the HIPPOCOR® corresponds to about 50 grams of fresh sea buckthorn berries. Various natural treasures are concentrated in the sea buckthorn.
Sea buckthorn seed lipid extract contains up to 90% unsaturated fatty acids, including polyunsaturated fatty acids:

– Alpha-linolenic acid (Omega-3);
– Linoleic acid (Omega-6);
– Oleic acid (Omega-9);
– Phytosterols (beta-sitosterol);
– As well as other fat-soluble vitamins and bioactive compounds.

Sea buckthorn seed lipid extract is produced using an innovative, sustainable and environmentally friendly technology – supercritical fluid extraction with carbon dioxide (CO2). The extraction method is gentle and efficient, ensuring that all active nutrients are preserved and concentrated in the final product.
The product dose not contains solvent (CO2) residues as it is converted back to the gaseous state after extraction.

HIPPOCOR® contains pure sea buckthorn seed lipid extract, it does not contain inorganic salts, proteins, fiber and food allergens.

Clinical trial of HIPPOCOR®

In 2021. the Research Institute of Cardiology and Regenerative Medicine of the University of Latvia started a clinical trial of the sea buckthorn seed lipid extract product HIPPOCOR® (Omega–3,6,9 fatty acids from sea buckthorn seeds)^1,2 in which patients with increased residual risk of cardiovascular disease are screened and enrolled*.
In addition to standard medical therapy and medications, enrolled patients take 2000 mg (two capsules) of the HIPPOCOR® food supplement. Up to now, in total 80 patients are screened and enrolled.
Currently, 49 patients who had been using HIPPOCOR® for three months are included in the trial.
Out of 49 patients, 46 patients have completed a three-month follow-up, in which it has been concluded that the product is safe for use (no adverse side effects were observed).
In addition, it has been observed that after 3 months of HIPPOCOR® use there is a tendency of improved blood pressure and glucose level. Furthermore, according to the currently available data, it can be concluded that the metabolism normalizes when HIPPOCOR® is used. Clinical trial of HIPPOCOR® continues, and it is planned to include more than 100 patients.

* Residual risk is the risk of macrovascular events and microvascular complications that persists in the majority of patients despite standard care, even achieving target low-density lipoprotein cholesterol levels and intensively monitoring arterial blood pressure and glucose levels (R3i International Steering Committee).

References:
¹ Sea Buckthorn Seed Oils as a Novel Omega 3 Source for Coronary Heart Disease Patients with Residual Risk, Iveta Mintale et al Medicina (Kaunas) 2022;58(Supplement 1);
² How to Reduce the Residual Cardiovascular Risk: Focus on Phytosterols, Kristaps Erglis et al Medicina (Kaunas) 2022;58 (Supplement 1).